恶性肿瘤中医证候与血栓弹力图检测相关性分析及其临床实践
摘要
[研究背景]
据报道,约15%的肿瘤患者在疾病的发展过程中有临床显性的静脉血栓栓塞症,血栓栓塞性疾病是目前癌症患者最常见的并发症和第二位死亡原因。采取积极的措施进行预防和治疗高凝状态,对改善恶性肿瘤患者的整体生活质量具有重要的积极意义。目前针对肿瘤高凝状态的西医抗凝药物主要有低分子肝素、维生素K拮抗剂、抗血小板药物等,但均具有出血风险大,且需反复抽血监测血凝,目前临床使用并未达成共识。如何防治恶性肿瘤血液高凝状态是目前研究热点之一,中医药在改善血凝状况、减轻临床症状,进而预防肿瘤转移与复发等方面均显示出一定的疗效,中药改善恶性肿瘤患者血液高凝状态的作用已得到越来越多的认可。但是目前关于恶性肿瘤高凝状态的中医临床研究相对较少,主观干预因素多,均限制了中医药治疗恶性肿瘤高凝状态的临床应用。凝血是一个非常复杂的过程,其中涉及到许多因子的相互作用,传统的实验室血凝检查只能反应凝血过程的某个孤立的部分,无法了解患者凝血功能全貌。血栓弹力图能以图形的方式,动态、完整地监测从凝血开始至血凝块形成及纤维蛋白溶解的全过程,对凝血因子、血小板功能、纤维蛋白原和纤维蛋白溶解等情况进行全面的检测和评估,其结果快速而准确,能更好的为临床服务。在此基础上,我们以血栓弹力图检测值作为判断高凝状态的探索性指标,开展了恶性肿瘤中医证候与血栓弹力图检测相关性探讨及其临床实践的研究。
[研究目的]
通过调查性临床研究,分析恶性肿瘤高凝状态与瘤种、分期、KPS评分、既往西医治疗等之间的相关性,分析恶性肿瘤患者中医常见证候分布,探索恶性肿瘤高凝状态与中医证候之间的关系,并通过临床实践,进一步探讨中医温阳益气、活血化痰法对改善恶性肿瘤高凝状态的临床疗效,为临床治疗提供参考。[研究方法]
第一部分：恶性肿瘤中医证候与血栓弹力图检测相关性分析。以2013年9月至2014年1月在东直门医院血液肿瘤科就诊的门诊恶性肿瘤患者为研究对象,制定调查表,收集病例。采用描述性分析了解患者一般资料、病情信息、血栓弹力图指标分布情况、中医证型分布情况；了解高凝组患者在各瘤种、临床分期、KPS评分、既往西医治疗中的构成比；并分析高凝组患者与中医各证型之间的关系；分析中医各证型与血栓弹力图指标R值、K值、Angle角值、MA值、CI值之间的关系。
第二部分：益气温阳、活血化痰法对血栓弹力图的影响。以2013年10月至2014年1月期间在北京中医药大学东直门医院血液肿瘤科就诊的门诊或病房的符合纳入标准的恶性肿瘤高凝状态患者为研究对象,对治疗前后的血栓弹力图指标、KPS评分以及安全性指标进行分析。观察中医温阳益气、活血化痰法对血栓弹力图的影响及安全性。
[结果]
①在所收集的215例恶性肿瘤患者中,气虚、血瘀、气滞、痰湿、阳虚均是临床常见的证候,其构成比分别为83.26%、66.05%、64.19%、52.09%和50.70%；②在恶性肿瘤患者中高凝状态与化疗、放疗无明显相关性(P>0.05),而与瘤种、临床分期、KPS评分、手术治疗具有一定关系(P<0.05)；③在各中医证型中,阳虚寒凝证与高凝状态关系密切(P<0.05),阳虚寒凝证患者中血液高凝状态的发生率较非阳虚寒凝证患者升高；④不同的中医证型(复合),血栓弹力图指标K值、Angle角值、CI值具有一定差异(P<0.05),阳虚寒凝组具有较高的Angle角值和CI值；⑤恶性肿瘤患者血液发生高凝的危险因素有：瘤种、肿瘤分期、阳虚寒凝证和Angle角值。⑥经益气温阳、活血化痰法治疗后,血栓弹力图指标Angle角值、MA值、CI值均较治疗前下降,K值较治疗前上升(P<0.05)；⑦益气温阳、活血化痰法能改善恶性肿瘤高凝状态患者生活质量(P<0.05)；⑧治疗前后生化指标比较无明显变化(P>0.05),未发生不良反应。
[结论]
1.阳虚寒凝证与恶性肿瘤高凝状态具有密切关联度。
2.瘤种、临床分期、KPS评分、手术治疗均与恶性肿瘤高凝状态具有一定的关联性。
3.气虚、血瘀、气滞、痰湿、阳虚均是恶性肿瘤患者临床常见证候,温阳益气、活血化痰理气法可作为恶性肿瘤的基本治疗策略。
4.益气温阳、活血化痰法能够改善恶性肿瘤患者血液高凝状态。
5.益气温阳、活血化痰法能够改善恶性肿瘤高凝状态患者生活质量。
6.益气温阳、活血化痰基本方具有较好的临床安全性。
Background:According to the report, about15%of the cancer patients had clinically overt venous thromboembolism, which is the most common complication in these patients and as the second cause of death. Taken active measures to prevent and treat hypercoagulable state has important positive significance in improve the overall quality of life of patients with malignant tumor. A lot of basic and clinical studies have proved that traditional Chinese medicine can effectively improve the hypercoagulable states of cancer patients, and have no significant adverse reactions. Traditional Chinese medicine has a large advantage in prevention and treatment of hypercoagulable state. However, current clinical research of traditional Chinese medicine on cancerous hypercoagulable state is relatively small, the differential treatment is confusion, and has lots of subjective intervention factors. That's greatly limitied the TCM treatment in clinical application for cancer patients with highcoagulation state. Coagulation is a very complex process, which involves the interaction of many factors. The traditional laboratory coagulation check only isolated parts of the clotting process, and can not understand the whole picture. Thrombelastogram can graphically dynamic, full monitoring the whole process of blood coagulation, from start to clot formation and fibrinolysis, comprehensive testing and evaluate coagulation factors, platelet function, fibrinogen and fibrin dissolution conduct and the results are fast and accurate, can better for clinical services. On this basis, we use thrombelastograph detection value as judged by a hypercoagulable state exploration targets, carried out a study to explore the relationship of cancer patients between TCM syndromes and thrombelastograph testing and its relevance to clinical practice.
Objectiver:Throughout the clinical research, study the correlation between cancer hypercoagulable state and tumor stage, KPS score and prior treatment. Analysis of the common syndrome distribution in cancer patients. Explore the relationship between cancer hypercoagulable state and TCM syndromes, and through clinical trials to further evaluate the clinical efficacy of improving cancer patients with hypercoagulable states by the therapeutic methods of Warming Yang and Invigorating Qi, promoting blood circulation and resolving phlegm.
Methods:Part one:We took the outpatients with cancer form Dongzhimen hospital during September2013and2014January as study cases, developed investigation table and collected case. Use descriptive research method to recognize the patient's general information, disease information, thrombelastograph index distribution and TCM syndromes. Then learn the ratio of tumor lesion site, clinical stage, KPS score and prior treatment in the hypercoagulable group. Third, analyze the relationship between cancerous hypercoagulable state and TCM syndromes. Forth, analyze the relationship between the syndromes and thrombelastograph index as R, K, Angle, MA and CI. Part two:We took the out and hospitalized patients with hypercoagulable state form Dongzhimen hospital during October2013and2014January for the study. Analyze thrombelastograph indicators and safety targets before and after the treatment. Observe the clinical efficacy and safety by the therapeutic methods of Warming Yang and Invigorating Qi, promoting blood circulation and resolving phlegm. Results:①In the collected215cases, qi deficiency, blood stasis, qi stagnation, phlegm, yang deficiency were common clinical syndromes, and its constituent ratio was83.26%,66.05%,64.19%,52.09%and50.70%respecily.②In the cancer patients the relationship between hypercoagulable states and chemotherapy, radiation therapy was not show (P>0.05), while the tumor lesion site, clinical stage, KPS score, surgical treatment has a certain relationship (P<0.05).③In various syndromes, the yang deficiency and coagulated cold syndrome closely related with hypercoagulable state (P<0.05), and has higher hypercoagulable states incidence compared with non-yang deficiency and coagulated cold syndrome patients.④The different syndromes (type two combination) have some differences with TEG index K value, Angle values and CI values (P<0.05), yang deficiency and coagulated cold syndrome group has a higher angle value and CI values.⑤Independent risk factor for the occurrence of cancer patients with blood hypercoagulable are:tumor stage, tumor location, yang deficiency and coagulated cold syndrome and Angle value.⑥After taking the Chinese medicine, the patients' thrombelastograph index angle value, MA value, CI values were all decreased, K values was rised (P<0.05).⑦The therapeutic methods of Warming Yang and Invigorating Qi, promoting blood circulation and resolving phlegm can improve the quality of life of cancer patients with hypercoagulable state (P<0.05).⑧Biochemical parameters before and after treatment showed no significant change (P>0.05), and adverse reactions did not occur. Conclusion:①Yang deficiency and coagulated cold syndrome is closely related to hypercoagulable state.②Tumor lesion site, clinical stage, KPS score, surgery and cancer treatment are have a certain relevance with hypercoagulable state.③Qi deficiency, blood stasis, qi stagnation, phlegm, Yang deficiency are common clinical syndromes in cancer patients, and yang qi, blood and Warming Yang and Invigorating Qi, promoting blood circulation and resolving phlegm and Qi method can be used as one of a basic treatment strategies in malignancies.④The rapeutic method of Warming Yang and Invigorating Qi, promoting blood circulation and resolving phlegm can improve the hypercoagulable state in patients with malignant tumors.⑤Warming Yang and Invigorating Qi, promoting blood circulation and resolving phlegm method can improve the quality of life of malignancy hypercoagulable state.⑥The rapeutic method of Warming Yang and Invigorating Qi, promoting blood circulation and resolving phlegm has a good clinical safety.
据报道,约15%的肿瘤患者在疾病的发展过程中有临床显性的静脉血栓栓塞症,血栓栓塞性疾病是目前癌症患者最常见的并发症和第二位死亡原因。采取积极的措施进行预防和治疗高凝状态,对改善恶性肿瘤患者的整体生活质量具有重要的积极意义。目前针对肿瘤高凝状态的西医抗凝药物主要有低分子肝素、维生素K拮抗剂、抗血小板药物等,但均具有出血风险大,且需反复抽血监测血凝,目前临床使用并未达成共识。如何防治恶性肿瘤血液高凝状态是目前研究热点之一,中医药在改善血凝状况、减轻临床症状,进而预防肿瘤转移与复发等方面均显示出一定的疗效,中药改善恶性肿瘤患者血液高凝状态的作用已得到越来越多的认可。但是目前关于恶性肿瘤高凝状态的中医临床研究相对较少,主观干预因素多,均限制了中医药治疗恶性肿瘤高凝状态的临床应用。凝血是一个非常复杂的过程,其中涉及到许多因子的相互作用,传统的实验室血凝检查只能反应凝血过程的某个孤立的部分,无法了解患者凝血功能全貌。血栓弹力图能以图形的方式,动态、完整地监测从凝血开始至血凝块形成及纤维蛋白溶解的全过程,对凝血因子、血小板功能、纤维蛋白原和纤维蛋白溶解等情况进行全面的检测和评估,其结果快速而准确,能更好的为临床服务。在此基础上,我们以血栓弹力图检测值作为判断高凝状态的探索性指标,开展了恶性肿瘤中医证候与血栓弹力图检测相关性探讨及其临床实践的研究。
[研究目的]
通过调查性临床研究,分析恶性肿瘤高凝状态与瘤种、分期、KPS评分、既往西医治疗等之间的相关性,分析恶性肿瘤患者中医常见证候分布,探索恶性肿瘤高凝状态与中医证候之间的关系,并通过临床实践,进一步探讨中医温阳益气、活血化痰法对改善恶性肿瘤高凝状态的临床疗效,为临床治疗提供参考。[研究方法]
第一部分：恶性肿瘤中医证候与血栓弹力图检测相关性分析。以2013年9月至2014年1月在东直门医院血液肿瘤科就诊的门诊恶性肿瘤患者为研究对象,制定调查表,收集病例。采用描述性分析了解患者一般资料、病情信息、血栓弹力图指标分布情况、中医证型分布情况；了解高凝组患者在各瘤种、临床分期、KPS评分、既往西医治疗中的构成比；并分析高凝组患者与中医各证型之间的关系；分析中医各证型与血栓弹力图指标R值、K值、Angle角值、MA值、CI值之间的关系。
第二部分：益气温阳、活血化痰法对血栓弹力图的影响。以2013年10月至2014年1月期间在北京中医药大学东直门医院血液肿瘤科就诊的门诊或病房的符合纳入标准的恶性肿瘤高凝状态患者为研究对象,对治疗前后的血栓弹力图指标、KPS评分以及安全性指标进行分析。观察中医温阳益气、活血化痰法对血栓弹力图的影响及安全性。
[结果]
①在所收集的215例恶性肿瘤患者中,气虚、血瘀、气滞、痰湿、阳虚均是临床常见的证候,其构成比分别为83.26%、66.05%、64.19%、52.09%和50.70%；②在恶性肿瘤患者中高凝状态与化疗、放疗无明显相关性(P>0.05),而与瘤种、临床分期、KPS评分、手术治疗具有一定关系(P<0.05)；③在各中医证型中,阳虚寒凝证与高凝状态关系密切(P<0.05),阳虚寒凝证患者中血液高凝状态的发生率较非阳虚寒凝证患者升高；④不同的中医证型(复合),血栓弹力图指标K值、Angle角值、CI值具有一定差异(P<0.05),阳虚寒凝组具有较高的Angle角值和CI值；⑤恶性肿瘤患者血液发生高凝的危险因素有：瘤种、肿瘤分期、阳虚寒凝证和Angle角值。⑥经益气温阳、活血化痰法治疗后,血栓弹力图指标Angle角值、MA值、CI值均较治疗前下降,K值较治疗前上升(P<0.05)；⑦益气温阳、活血化痰法能改善恶性肿瘤高凝状态患者生活质量(P<0.05)；⑧治疗前后生化指标比较无明显变化(P>0.05),未发生不良反应。
[结论]
1.阳虚寒凝证与恶性肿瘤高凝状态具有密切关联度。
2.瘤种、临床分期、KPS评分、手术治疗均与恶性肿瘤高凝状态具有一定的关联性。
3.气虚、血瘀、气滞、痰湿、阳虚均是恶性肿瘤患者临床常见证候,温阳益气、活血化痰理气法可作为恶性肿瘤的基本治疗策略。
4.益气温阳、活血化痰法能够改善恶性肿瘤患者血液高凝状态。
5.益气温阳、活血化痰法能够改善恶性肿瘤高凝状态患者生活质量。
6.益气温阳、活血化痰基本方具有较好的临床安全性。
Background:According to the report, about15%of the cancer patients had clinically overt venous thromboembolism, which is the most common complication in these patients and as the second cause of death. Taken active measures to prevent and treat hypercoagulable state has important positive significance in improve the overall quality of life of patients with malignant tumor. A lot of basic and clinical studies have proved that traditional Chinese medicine can effectively improve the hypercoagulable states of cancer patients, and have no significant adverse reactions. Traditional Chinese medicine has a large advantage in prevention and treatment of hypercoagulable state. However, current clinical research of traditional Chinese medicine on cancerous hypercoagulable state is relatively small, the differential treatment is confusion, and has lots of subjective intervention factors. That's greatly limitied the TCM treatment in clinical application for cancer patients with highcoagulation state. Coagulation is a very complex process, which involves the interaction of many factors. The traditional laboratory coagulation check only isolated parts of the clotting process, and can not understand the whole picture. Thrombelastogram can graphically dynamic, full monitoring the whole process of blood coagulation, from start to clot formation and fibrinolysis, comprehensive testing and evaluate coagulation factors, platelet function, fibrinogen and fibrin dissolution conduct and the results are fast and accurate, can better for clinical services. On this basis, we use thrombelastograph detection value as judged by a hypercoagulable state exploration targets, carried out a study to explore the relationship of cancer patients between TCM syndromes and thrombelastograph testing and its relevance to clinical practice.
Objectiver:Throughout the clinical research, study the correlation between cancer hypercoagulable state and tumor stage, KPS score and prior treatment. Analysis of the common syndrome distribution in cancer patients. Explore the relationship between cancer hypercoagulable state and TCM syndromes, and through clinical trials to further evaluate the clinical efficacy of improving cancer patients with hypercoagulable states by the therapeutic methods of Warming Yang and Invigorating Qi, promoting blood circulation and resolving phlegm.
Methods:Part one:We took the outpatients with cancer form Dongzhimen hospital during September2013and2014January as study cases, developed investigation table and collected case. Use descriptive research method to recognize the patient's general information, disease information, thrombelastograph index distribution and TCM syndromes. Then learn the ratio of tumor lesion site, clinical stage, KPS score and prior treatment in the hypercoagulable group. Third, analyze the relationship between cancerous hypercoagulable state and TCM syndromes. Forth, analyze the relationship between the syndromes and thrombelastograph index as R, K, Angle, MA and CI. Part two:We took the out and hospitalized patients with hypercoagulable state form Dongzhimen hospital during October2013and2014January for the study. Analyze thrombelastograph indicators and safety targets before and after the treatment. Observe the clinical efficacy and safety by the therapeutic methods of Warming Yang and Invigorating Qi, promoting blood circulation and resolving phlegm. Results:①In the collected215cases, qi deficiency, blood stasis, qi stagnation, phlegm, yang deficiency were common clinical syndromes, and its constituent ratio was83.26%,66.05%,64.19%,52.09%and50.70%respecily.②In the cancer patients the relationship between hypercoagulable states and chemotherapy, radiation therapy was not show (P>0.05), while the tumor lesion site, clinical stage, KPS score, surgical treatment has a certain relationship (P<0.05).③In various syndromes, the yang deficiency and coagulated cold syndrome closely related with hypercoagulable state (P<0.05), and has higher hypercoagulable states incidence compared with non-yang deficiency and coagulated cold syndrome patients.④The different syndromes (type two combination) have some differences with TEG index K value, Angle values and CI values (P<0.05), yang deficiency and coagulated cold syndrome group has a higher angle value and CI values.⑤Independent risk factor for the occurrence of cancer patients with blood hypercoagulable are:tumor stage, tumor location, yang deficiency and coagulated cold syndrome and Angle value.⑥After taking the Chinese medicine, the patients' thrombelastograph index angle value, MA value, CI values were all decreased, K values was rised (P<0.05).⑦The therapeutic methods of Warming Yang and Invigorating Qi, promoting blood circulation and resolving phlegm can improve the quality of life of cancer patients with hypercoagulable state (P<0.05).⑧Biochemical parameters before and after treatment showed no significant change (P>0.05), and adverse reactions did not occur. Conclusion:①Yang deficiency and coagulated cold syndrome is closely related to hypercoagulable state.②Tumor lesion site, clinical stage, KPS score, surgery and cancer treatment are have a certain relevance with hypercoagulable state.③Qi deficiency, blood stasis, qi stagnation, phlegm, Yang deficiency are common clinical syndromes in cancer patients, and yang qi, blood and Warming Yang and Invigorating Qi, promoting blood circulation and resolving phlegm and Qi method can be used as one of a basic treatment strategies in malignancies.④The rapeutic method of Warming Yang and Invigorating Qi, promoting blood circulation and resolving phlegm can improve the hypercoagulable state in patients with malignant tumors.⑤Warming Yang and Invigorating Qi, promoting blood circulation and resolving phlegm method can improve the quality of life of malignancy hypercoagulable state.⑥The rapeutic method of Warming Yang and Invigorating Qi, promoting blood circulation and resolving phlegm has a good clinical safety.
引文
1. Reikvam H,Steien E,Hauge B,et al.Thrombelastography[J].Transfus Apher Sci,2009,40(2):119-123.
2. Michelson AD.Methods for the measurement of platelet function[J].Am J Cardiol,2009,103(3 Suppl):20-26.
3. Bischof D,Dalbert S,Zollinger A,et al.Thrombelastography in the surgical patient[J].Minerva Anestesiol,2010,76(2):131-137.
4. Ganter MT,Hofer CK.Coagulation monitoring: current techniques and clinical use of viscoelastic point of care coagulation devices[J].Anesth Analg,2008,106(5):1366-1375.
5. Brohi K,Cohen MJ,Ganter MT,et al.Acute coagulopathy of trauma:hypoperfusion induces systemic anticoagulation and hyperfibrinolysis[J].J Trauma,2008,64(5):1211-1217.
6. Niles SE,Melaughlin DF,Perkins JG,et al.Increased Mortality associated with the early coagulopathy of traum in combat casualties[J].J Trauma,2008,64(6):1459-1463.
7. Kaufmann CR,Dwer KM,John D,et al.Usefulness of thembelastography in assessment of trauma patient coagulation[J].J Trauma, 1997,42(4):716-720.
8. Lier H,Krep H,Schochl H.Coagulatlon management in the treatment Of multiple trauma[J]. Anaesthesist,2009,58(10):1010-1026.
9. Stahel PF,Moore EE,Schreier SL,et al.Transfusion state Gies in pose injury coagulopathy[J].Curt Opin AnaesthesioL,2009,22:289-298.
10. Carroll RC,Craft RM,Langdon RJ,et al.Early evaluation of acute traumatic coagulopathy by thrombehstogmphy[J].Translational Research,2009,154(1):34-39.
11.Schreiber MA,Differding J,Thorborg P, et al.Hypercoagulability is most prevalent early after injury and in female patients[J].Trauma,2005,58(3):475-480.
12.蔡海英,叶立刚,徐善祥等.血栓弹力图在严重多发伤患者中的初步应用[J].中华创伤杂志,2011,27(12)：1115-1117.
13. Jeffry L,Ernest E,Michael Sawyer,et al.Primary Fibrinolysis Is Integral in the Pathogenesis of the Acute Coagulopathy of Trauma[J]. Annals ofSurgery,2010,252(3)：434-444.
14. Michael Nekludov,Bo Michael Bellander,Margareta Blomb,et al.Platelet Dysfunction in Patients with Severe Traumatic Brain Injury[J].NEUROTRAUMA,2007,24:1699-1706.
15. Max V Wohlauer,Ernest E Moore,Scott Thomas,et al.Early Platelet Dysfunction: An Unrecognized Role in the Acute Coagulopathy of Trauma[J].Am Coll Surg,2012,01(50):739-746.
16. Levrat A,Gros A,Rugeri L,et al.Evaluation of rotation thrombelastography for the diagnosis of hypefibrinolysis in trauma patients[J].Br J Anaesth,2008,100(6):792-797.
17. Brenni M,Wom M,Brueseh M,et al.Suecessful rotational thromboelastometry guided treatment of traumatic haemorrhage hypefibrinolysis and coagulopathy [J].Acta Anaesthesiol Seand,2010,54(1):111-117.
18. Johansson PI,Stensballe J. Effect of Haemostatic Control Resuscitation on mortality in massively bleeding patients:a before and after study[J]. Vox Sang,2009,96(2):111-118.
19. Bryan A,Gabriel Faz,Hatch,et al.Rapid Thrombelastography Delivers Real-Time Results That Predict Transfusion Within 1 Hour of Admission[J]. J Trauma Injury,Infection,and Critical Care,2011,71 (2):407-417.
20. Victor Jeger,Aristomenis K.Can Rapid TEG Accelerate the Search for Coagulopathies in the Patient With Multiple Injuries[J].TRAUMA-Injury,Infection, and Critical Care,2009,66(4):1253-1257.
21. Victor Jeger,Sandra Willi,Tun Liu,et al.The Rapid TEG a-Angle May Be a Sensitive Predictor of Transfusion in Moderately Injured Blunt Trauma Patients[J].The Scientific World Journal,2012:821794.
22. Wilson D,Cooke EA,McNatly MA,et al.Changes in coagulability as measured by thrombelastography following surgery for proximal femoral fracture[J].Injury,2001,32(10):765-770.
23. Bryan A,Kristin M,Zayde A,et al.Admission rapid thrombelastography predicts development of pulmonary embolism in trauma patients[J].J Trauma Acute Care Surg,2012,72(6):1470-1477.
24.彭南海,叶向红,陈月英.凝血功能监测预防腹部创伤术后深静脉血栓的护理研究[J].护理学杂志,2013,28(8)：65-67.
25. Jeffry L,Ernest E,Allison Sabel,et al.Rapid thrombelastography(r-TEG) identifies hypercosguhbility and predicts thromboembolic evens in surgical patients[J].Surgery,2009,146(4):764-774.
26. Senzolo M,Agarwal S,Zappoli P, et al.Heparin-like effect contributes to the coagulopathy in patients with acute liver failure undergoing liver transplantation [J]. Liver Int,2009,29(5):754-759.
27. Agarwal S,Senzolo M,Melikian C,et al.The prevalence of a heparinlike effect shown on the thromboelastograph in patients undergoing liver transplantation[J]. Liver Transpl,2008,14(6):855-860.
28. Kang YG,Martin OJ,Marquez J,et al.Intraoperative changes in blood coagulation and thromboelastographic monitoring in liver transplantation[J].Anesth Analg,1985,64:888.
29. de Pietri L,Masetti M,Montalti R,et al.Use of recombinant factor IX and thromboelastography in a patient with hemophilia B undergoing liver transplantation: a case report[J].Transplant Proc,2008,40(6):2077-2079.
30.寇建涛,樊华,李立新等.血栓弹力图在终末期肝硬化肝移植患者围手术期的应用(附27例报告)[J].器官移植,2011,2(6)：310-313.
31. Whitson BA,HuD-Dleston SJ,Savik K,et al.Bloodless cardiac surgery is associated with decreased morbidity and mortality[J].J Card Surg,2007,22(5):373-378.
32. Ak K,Isbir CS,Tetik S,et al.Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG:a prospective randomized study[J].J Card Surg,2009,24(4):404-410.
33.杨丽君,林茹,叶莉芬等.血栓弹力图在小儿体外循环围术期的应用价值[J].中国体外循环杂志,2013,11(1)：11-14.
34. Kenneth J, Tuman MD, Robert J, et al.Evalution of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelatographic assay[J].J Cardiothroac Vasc Anesth,1994,8:144-149.
35. Artang R,Frandsen NJ,Nielsen JD.Application of basic and composite thrombelastography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin:an in vivo study[J]. Thromb J,2009,7(1):14.
36.纪宏文,马丽,高旭蓉等.血栓弹力图在体外循环心血管手术的应用[J].中国体外循环杂志,2011,9(3)：170-172.
37. Cosmi B,Alatri A,Cattaneo M, et al.Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures:guidelines of the Italian society for haemostasis and thrombosis (SISET)[J].Thromb Res,2009,124(5):6-12.
38. Westbrook AJ,Olsen J,Bailey M,et al.Protocol based on thromboelastograph(TEG) out-performs physician preference using laboratory coagulation tests to guide blood replacement during and after cardiac surgery:a pilot study [J]. Heart Lung Circ,2009,18(4):277-288.
39. Taneja R,Fernandes P,Marwaha G,et al.Perioperative coagulation management and blood conservation in cardiac surgery:a canadian survey [J].J Cardiothorac Vasc Anesth,2008,22(5):662-669.
40. Differding JA,Underwood SJ,Van PY, et al.First Place Resident's Competition:trauma induces a hypercoagulable state that is resistant to hypothermia as measured by thrombelastogram[J].Am J Surg,2011,201(5):585-589.
41.Ruttmann TG,Lemmens HJ,Malott KA,et al.The haemodilution enhanced onset of coagulation as measured by the thrombelastogram is transient[J].Eur J Anaesthesiol,2006,23(7):574-579.
42. Karoutsos S,Nathan N,Lahrimi A,et al.Thrombelastogram reveals hypercoagulability after administration of gelatin solution[J].Br J Anaesth,1999,82(2):175-177.
43. Hobson AR,Agarwala RA,Swallow RA,et al.Thrombelastography:current clinical applications and its potential role in interventional cardiology. Platelets,2006,17(8):509-518.
44.徐志红,胡家安,权薇薇等.血栓弹力图评价老年冠心病合并睡眠呼吸暂停综合征患者高凝状态的临床价值[J].血栓与止血学,2012,18(3)：112-119.
45.何银华,李飞.急性脑梗死患者血栓弹力图临床研究[J].检验医学,2011,26(3)：163-165.
46.肖莉,陈永武,谢俊刚.肺癌患者血栓弹力图检测的临床意义[J].肿瘤防治研究,2000,27(3)：213-214.
47.王莉,裴文仲,杨建东等.血栓弹力图在恶性肿瘤高凝状态诊断中的应用价值[J].实用临床医药杂志,2013,17(11)：119-121.
48. Chen A,Teruya J.Global hemostasis testing thromboelastography:old echnology,new applications[J].Clin Lab Med,2009,29(2):391-407.
49.龚波,俞菁,胡荷宇等.用血栓弹力图分析仪检测不同妊娠期孕妇的凝血功能[J].临床检验杂志,2012,30(6)：475-476.
50. Sharma SK,Philip J,Wiley J.Thromboelastographic changes in healthy parturients and postpartum women[J].Anesth Analg,1997,85(1):94-98.
51.章莉,俞菁,侯雅萍等.用血栓弹力图监测妊娠合并血小板减少症孕妇凝血功能[J].临床检验杂志,2013,31(7)：487-489.
52. Roeloffzen WW, Kluin-Nelemans HC,Mulder AB,et al.Thrombocytopenia affects plasmatic coagulation as measured by thrombelastography[J].Blood Coagul Fibrinolysis,2010,21 (5):389-397.
53. Slichter SJ.Relationship between platelet count and bleeding risk in thrombocytopenic patients[J].Trans Med Rev,2004,18(3):153-167.
54. Reikvam H,Steien E,Hauge B,et al.Thrombelastography[J].Trans Apher Sci,2009,40(2):119-123.
55.左艳,娄世锋,张颖等.血栓弹力图在重度血小板减少者中的应用[J].医学与临床,2011,8(16)：1931-1934.
56.黄晓英,韩旭东,王芳等.血栓弹力图评价肝病不同阶段凝血功能的改变[J].胃肠病学和肝病学杂志,2010,19(6)：537-539.
57.陈家华,廖建梅,殷建国等.血栓弹力图在肝硬化患者围术期的应用[J].江苏医药,2005,31(11)：827-829.
58.李存江,张石江,邵永丰等.肝素酶修正的血栓弹力图在冠脉搭桥术前的应用[J].江苏医药,2013,39(4)：438-440.
59.燕姿辰,杨新春,周丽娜.血栓弹力图评价肝素浓度变化对凝血功能影响的价值[J].山东医药,2012,52(31)：7.
60. MATZELLE SJ,GIBBS NM,WEIGHTMAN W, et al.Systemic anticoagulant effect of low-dose subcutaneous unfractionated heparin as determined using thrombelastography[J]. Anaesth Intensive Care.2007,35(4):498-504.
61.BOYCE H,HUME-SMITH H,NG J, et al.Use of thromboelastography to guide thromboprophylaxis after caesarean section[J].Int J Obstet Anesth,2011,20(3):213-218.
62. Mercedes P.Disseminated intravascular coagulation[J].ICS,2002,1237:163-168.
63.肖菲,金晓东,魏永刚等.血栓弹力图在诊断DIC中的价值探讨[J].四川大学学报：医学版,2008,39(3)：521-522.
64. Rasoul Ferasatkish,Hossein NaD-Dafnia,Seyed-Mostafa Alavi,et al.Diagnosis and Treatment of Disseminated Intravascular Coagulation:A Case Report.Arch Iranian Med,2007,10(3):404-408.
65.黄婷婷,任艺虹.血栓弹力图对弥漫性血管内凝血的诊疗价值.中华心血管病杂志,2011,5(39)：461.
66. Carroll RC,Worthington RE,Craft RM,et al.Post interventional cardiology urinary thromboxane correlates with platelet mapping detected aspirin resistance[J].Thromb Res,2010,125(4):e118-122.
67. Rivard GE,Brummel-Ziedins KE,Mann KG,et al.Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography[J].J Thromb Haemost,2005,3(9):2039-2043.
68. Bliden KP,Dichiara J,Tantry US,et al.Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? [J].J Am Coll Cardiol,2007,49(6):657-666.
69. Bochsen L,Wiinberg B,Kjelgaard-Hansen M,et al.Evaluation of the TEG platelet mapping assay in blood donors[J].Thromb J,2007,5:3.
70. Gurbel PA,Bliden KP,Hiatt BL,et al.Clopidogrel for coronary stenting: response variability, drug resistance,and the effect of pretreatment platelet reactivity [J].Circulation,2003,107(23):2908-2913.
71. Gurbel PA,Bliden KP,Guyer K,et al.Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting[J].Thromb Res,2007,119(5):563-570.
72. Gurbel PA,Bliden KP,Navickas IA,et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting is chemic events[J].Am Heart J,2010,160:346-354.
73. Swallow RA,Agarwala RA,Dawkins KD,et al.Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy[J].Platelets,2006,17(6):385-392.
74. Hobson AR,Petley GW,Dawkins KD,et al.A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography [J].Platelets,2007,18(7):497-505.
75.任艺虹,盖鲁粤,杨庭树等.改良血栓弹力图法和流式细胞测定技术对血小板活性抑制程度的比较研究[J].中华心血管病杂志,2007,35(4)：366-367.
76.王洪叶,唐发宽,肖军.冠状动脉支架术后发生再缺血事件与血小板活性有关[J].心脏杂志,2010,22(5)：F002.
77. Orlikowski CE,Rocke DA,Murray WB,et al.Thrombelastography changes in preeclampsia and eclampsia. Br J Anaesth,1996,77(2):157-161.
78. Dickinson KJ,Troxler M,Homer-Vanniasinkam S.The surgical application of point of care haemostasis and platelet function testing. Br J Surg,2008,95(11):1317-1330.
1. Elalamy I,Verdy E,Gerotziafas G,etal.Pathogenesis of venous thromboembolic disease in cancer[J]. Pathol Biol(Paris),2008,56(4):184-194.
2. Korte W. Cancer and thrombosis:An increasingly important association[J].Support Care Cancer,2008,16(3):223-228.
3.曹利平,王向阳,苗文红等.谢远明临证思辨特点[J].陕西中医,2007,28(12)：1659-1661.
4.赵凤达.洪广祥治疗晚期肺癌的经验[J].新中医,1996(3)：3-4.
5.唐武军,王笑民.郁仁存治疗肿瘤“内虚学说”初探[J].北京中医药,2011,30(3)：186-188.
6.沈霖,杨艳萍.朱曾柏教授治疗恶性肿瘤经验[J].新中医,1989,4：19-21.
7.王笑民,郁仁存,王禹堂等.晚期非小细胞肺癌患者气虚血瘀证的研究[J].中国中西医结合杂志,1994,14(12)：724-726.
8.司富春,侯红丽,刘瑜等.甲状腺肿瘤的中医证型和方药分析.中华中医药学会中医方证基础研究与临床应用学会研讨会论文集：197-203.
9.张娟,王鹏,刘鲁明.胰腺癌中医证候分析[J].中华中医药杂志,2012,27(3)：579-581.
10.汪天喜.恶性骨肿瘤围化疗期中医证候规范化初步研究.硕士,广州中医药大学.2009.
11.沈旭波,侯凤刚,刘庆.原发性肝癌1368例中医单证出现状况文献分析[J].中医药学刊,2004,22(1)：69-70.
12.王禹堂,王笑民,郁仁存.癌症患者的血瘀证研究[J].中国医药学报,1996,11(6)：57.
13.孙红,李萍萍.乳腺癌中医证候分类与预后相关性的初步研究[J].中国中医基础医学杂志,2003,9(2)：72-73.
14.李道睿,张培彤,胡晓梅等.300例中晚期原发性支气管肺癌血瘀证分布规律的调查研究[J].中国中医药信息杂志.2007,14(3)：19-21.
15.周阿高,丁红熊,陈梅芳等.140例胃部恶性肿瘤患者手术前后和死亡前血瘀证研究[J].中西医结合杂志,1990,10(9)：540-541.
16.朱建红,朱起贵.中医对微循环的若干认识[J].微循环杂志,2002,12(2)：41-43.
17.田牛,李玉珍,刘育英.血瘀证的微循环研究[J].中国中西医结合杂志,2001,21(4)：248-249.
18.田牛,等.微循环方法学[M].北京：原子能出版社,1987,5.
19.陈泽霖,等,舌诊研究[M].第二版.北京：上海科学技术出版社,1982,225.
20.陆远志.微循环基础与临床[M].北京：人民军医出版社,1986：269.
21.魏艾红.自血病舌质及血疲病理研究[J].中国医药学报,1995,10(5)：11.
22.陈泽民,李泽浩,江建平等.肝癌病人舌质与微循环的关系—附100例临床分析[J].中西医结合肝病杂志,1999,9(3)：44-45.
23.万晓燕,任东峰.桃红四物汤加味配合功能锻炼治疗乳腺癌术后上肢肿胀21例[J].吉林中医药,2007,27(11)：30.
24.张传芳.恶性肿瘤患者临床与血液黏度变化探讨[J].中国现代医学杂志,2004,14(7)：73-78.
25.胡庆福,陈泽霖,陈依萍等.血瘀型恶性肿瘤病人红细胞膜流动性及血液流变性的观察[J].肿瘤,1990,(7)：10.
26.翁维良,崔晶,王怡.冠心病心绞痛患者259例血液粘度测定[J].中华心血管病杂志,1984,12(3)：183.
27.翁维良.脑血栓血瘀证患者红细胞变形性等客观检测指标的探讨[J].中西医结合杂志,1988,8(7)：424.
28.须惠仁,傅湘琦,向丽华等.肝郁证的动物实验研究—激怒刺激对大白鼠血液流变学的影响[J].中医杂志,1991,32(6)：44-46.
29.丘瑞香,罗致强,朱雅宜等.冠心病血瘀证血液理化特性与中医证型相关性研究[J].中医杂志,2002,43(5)：378-379.
30.叶兴涛.肺癌瘀血舌质与血液流变学变化的相关性分析[J].中国中医药科技,2012,19(3)：196-197.
31.富琦,张晨曦,杨国旺等.恶性肿瘤患者凝血指标临床分析及其与血瘀证的相关性[J].中医杂志,2011,52(23)：2024-2030.
32.李晓惠,张文曦,倪海雯.恶性血液病血瘀证的研究[J].南京中医药大学学报(自然科学版),2000,16(3)：146-147.
33.刘永惠,杨晓峰,周冬枝.肿瘤血瘀证实质及活血化瘀治则的研究[J].河北中医,2002,24(4)：252-254.
34.王缨,李国贤.慢性肾衰竭患者血液流变学指标及血液粘滞综合征与血瘀证关系的研究[J].中国中西医结合肾病杂志,2003,4(2)：92-95.
35.李晓明.肾脏病血瘀证患者血浆内皮素Q颗粒膜蛋白140含量测定的意义[J].中国中医基础医学杂志,1996,2(5)：35.
36.施赛珠,石志芸,陈剑秋等.血瘀证与血小板活化的关连研究[J].中国中医基础医学杂志,1996,2(4)：22.
37.石志芸,李晓明,陈剑秋.血小板Q颗粒膜蛋白140检测在“病”与“证”的特异性联系[J].中国中医基础医学杂志,1997,3(1)：35.
38.陈永斌,阮玉山,黄李平等.脑挫裂伤血瘀证患者血小板活化分子CD62P和TSP的改变及临床意义[J].广西医科大学学报,2007,24(2)：192-194.
39.徐西,廖家帧,王硕仁等.310例血瘀证患者血小板功能与中医辨证关系的临床研究[J].中国中西医结合杂志,1993,13(12)：718-722.
40.叶向荣,张素芬.益气活血与理气活血对血瘀证大鼠血小板5-轻色胺、丙二醛和血浆血 栓素及6-酮-前列腺素的影响[J].山东中医药大学学报,1997,21(1)：76-77.
41.蓝肇熙,李薇,张进陶等.损伤血瘀证中PAF变化及桃红四物汤对其干预的实验研究[J].四川中医,2007,25(10)：9-11.
42.陈利国,孙兆贵,王蕾等.血瘀证与血管内皮细胞内游离钙浓度关系的实验研究[J].山东中医药大学学报,2001,25(1)：55-57.
43.陈利国,陈畅宏,屈援等.血府逐瘀汤对血瘀证大鼠血管内皮细胞黏附分子表达的影响[J].山东中医药大学学报,2006,30(5)：395-398.
44.黄敏,谢建祥,吴锐等.血瘀证目征与血管内皮细胞损伤的关系[J].中华中医药杂志,2011,26(4)：781-784.
45.江欢,周岩,孙晓红等.中医“热毒血瘀证”模型大鼠血管内皮损伤及血小板功能障碍研究[J].中西医结合心脑血管病杂志,2009,7(4)：425-428.
46.罗晓琴,徐咏梅,唐勇等.从肿瘤转移相关因子探讨非小细胞肺癌气虚血瘀证的病理基础[J].中国中西医结合杂志,2009,29(10)：886-888.
47.王奇,陈云波,赖世隆等.血府逐瘀汤对用血瘀证兔血清损伤的血管内皮细胞的形态学影响[J].广州中医药大学学报,2001,18(2).105-109.
48.王奇,陈云波,赖世隆等.血府逐瘀汤对血瘀证兔模型血清损伤的血管内皮细胞内分泌功能的影响[J].中国实验方剂学杂志,2002,8(2).12-14.
49.蔡钦朝,汪琼华,吴云智等.血瘀证患者血管内皮内分泌功能的观察.安徽中医学院学报,1998,17(2)：61-63.
50.崔同建,陈香莲,蒋云林等.复发转移大肠癌血瘀证与外周血PTEN、CD44基因表达相关性分析[J].福建中医药大学学报,2011,21(4)：1-4.
51.崔同建,陈香莲,蒋云林等.晚期大肠癌的病性证素与外周血p53、nm23的相关性研究[J].现代消化及介入诊疗,2011,16(4)：235-238.
52.陈怡宏.胃癌血瘀证基因表达及细胞信号信道蛋白表达的研究.广州中医药大学,硕士,2002.
53.姜林.胃癌血瘀证与p53、C-erbB-2、VEGF表达的相关性研究.湖北中医学院,硕士,2008.
54.吴朝泰.血瘀证与胃癌及癌前期病变肿瘤相关基因表达的关系.广州中医药大学,硕士,2000.
55.赵海燕,屠德敬,夏溪等.6例姑息治疗期大肠癌血瘀证血清蛋白质组学探索性研究[J].中华中医药学刊,2012,30(8)：1777-1779.
56.李雪梅,许玥,林华胜等.中晚期非小细胞肺癌MGMT基因甲基化表达与中医证型的相关性研究[J].四川中医,2012,30(5)：36-38.
57. Caine GJ,Stonelake PS.Lip GY The hypereoagulable state of malignaney:pathogenesis and eurrent debate[J].Neophlasia,2002,4(6):465-473.
58. Lopez JA,Kearon C,LeeAYY. Deepvenous thrombosis[M].Am Soc Hematol Educationnal Book,2004,439-456.
59. Otten HM,Mathijssen J,Cate HT,et al.Symptomatic venous thromboembosis in cancer Patients treated with chemotherapy:An underestimated Phenomenon[J].Arch Inter Med,2004,164(2):190-194.
60. VersoM,Agnelli G.Venous thromboembolism associated with longterm use of central venous catheters in cancer Patients[J].J Clin Oncol,2003,21(19):3665-3675.
61.孙校男,郭勇.大肠癌辅助化疗期血瘀证血清蛋白质组学探究[J].中华中医药学刊,2013,31(5)：1081-1084.
62.金伟,哈木拉提·吾甫尔等.恶性肿瘤血瘀证型血栓前状态分子标志物测定及其意义[J].Chinese Journal of Information on TCM,2009,16(10):18-21.
63.蒋霆辉,陈越,潘龙赐等.晚期恶性肿瘤患者血栓前状态检测指标与中医证型的相关性研究[J].上海中医药大学学报,2010,24(2)：31-33.
64.张乐,王彬彬,舒琦瑾.大肠癌临床分期及中医证型与血浆D-二聚体的相关性研究[J].浙江中医杂志,2010,45(2)：96-97.
65.严常开,刘惟莞.丹参素胶囊活血化瘀作用的实验研究[J].中成药,2003,25(8)：637-639.
66.姜开余,顾振伦.丹参素对CDllb. P-selectin. ICAM-1、VCAM-1、E-selectin表达的影响[J].中国药理学通报,2000,16(6)：682-685.
67.樊淑梅,任宝军,翟英姬.丹参注射液对胃癌术后患者血液高凝状态的影响[J]Chinese Journal of New Drugs,2012,21(21):2535-2538.
68.刘锦蓉,叶松柏.川芎嗪抗肿瘤转移作用及其机理[J].中国药理学与毒理学杂志,1993,7(2)：149-152.
69.王生,赵杨,陶丽等.川芎嗪对肿瘤介导的血液高凝的影响中国[J].中国药理学通报,2012,28(5)：709-715.
70.冯婧,田菲.川芎嗪注射液改善恶性肿瘤患者血液高凝状态60例临床观察[J].山西中医学院学报,2010,11(5)：24-25.
71.李麒,陈泽涛.活血化瘀法改善原发性支气管肺癌高凝状态临床观察[J].辽宁中医药大学学报,2013,15(8)：182-185.
72.胡国志,武英蕾等.金龙胶囊改善恶性肿瘤化疗患者高凝状态的临床分析[J].中国肿瘤临床,2012,39(22)：1846-1848.
73.李春越.血瘀证及活血化瘀方药研究进展[J].中西医结合杂志,1988,8(5)：317-320.
74.白刚,肖供彬.中药方剂研究与应用大全[M].北京：中国科学技术出版社,1995：43.
75.王阶,荆鲁等.血府逐瘀汤拆方临床研究[J].中国中药杂志,2004,29(8)：803-806.
76.张红,王靖,张志芳.血府逐瘀汤加味治疗中晚期非小细胞肺癌血瘀证临床疗效及血流变指标观察[J]Clinical Journal of Chinese Medicine,2012,4(14):8-11.
77.李莉芳.杏丁注射液治疗急性脑梗死30例临床分析[J].北京中医药,2008,27(5)：365-367.
78.刘建德.杏丁注射液对肺癌患者高凝血状态的影响[J].当代医学,2008,14(22)：150-151.
79.魏里平,姜海量,王来界.水蛭素的药理作用中国中医基础研究杂志,2004,15(8)：236-239.
80.唐莉,段巧虹,范平生.水蛭治疗恶性肿瘤高凝状态临床研究[J].中医药临床杂志,2012,24(9)：871-872.
81.崔巍,精世杰,藤静茹等.活血化瘀中药抑制肿瘤细胞—血小板聚集的实验研究[J].中国中医基础医学杂志,1997,3(1)：27-28,31.
82.姜林,孔庆志.活血化瘀药抗肿瘤作用的实验研究概况[J].湖北中医杂志,2008,30(8)：63.
83.迟惠昌,胡凤山,张青等.益气活血中药配合化学药物治疗晚期胃癌疗效观察[J].中华中医药杂志,2011,26(8)：1888-1890.
84.胡艳,侯安继,周莉,俞雷.益气活血方对中晚期非小细胞肺癌高凝状态作用的临床研究[J].辽宁中医杂志,2011,38(12)：2330-2332.
85.邓生明,陆用莲,林小清.益气活血方对中晚期非小细胞肺癌高凝状态作用运用分析[J].Clinical Journal of Chinese Medicine,2012,4(18):74-75.
86.朱凯,潘迎英,杨怡敏.益气活血方对恶性肿瘤血瘀证的影响研究[J].实用中医杂志,2012,28(2)：90.
87.王炳胜,张秀丽,王涛等.益气活血中药治疗恶性肿瘤高纤维蛋白原血症疗效观察[J].中国中医急症,2003,12(6)：517-518.
88.毕宏观,王俊茄,张柯楠等.参麦注射液对恶性肿瘤患者血液流变性及微循环的影响[J].中国医学物理学杂志,2005,22(5)：675-676.
89.朱玲,周黎明,王正荣.参附注射液的作用及作用机制的研究进展[J].四川生理科学杂志,2004,26(2)：77-82.
90.梁桦,周桥灵,杨承祥等.参附注射液对妇科恶性肿瘤根治术患者围术期血液高黏滞和高凝状态的影响[J].广东医学,2013,34(11)：1747-1749.
1. Korte W. Cancer and thrombosis:An increasingly important association[J].Support Care Cancer, 2008,16(3):223-228.
2. Farge D, Durant C,Villiers S,et al.Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients [J].Thromb Res,2010,125(Supp12):S108-116.
3. Elalamy I,Verdy E,Gerotziafas G,et al. Pathogenesis of venous thromboembolic disease in cancer [J].Pathol Biol(Paris),2008,56(4):184-194.
4.林胜友,沈敏鹤,舒静娜等.780例大肠癌中医证型分类特征的回顾性分析[J].浙江中医药大学学报,2011,35(3)：322-324.
5.黎敬波,张征,林丽珠,等.非小细胞肺癌417例证候分布的临床研究[J].广州中医药大学学报,2009,26(1)：73-77.
6.孙建立,李春杰,李和根等.刘嘉湘扶正法治癌学术思想介绍[J].当代名医,2006,47(11)：814-816.
7.唐武军,王笑民.郁仁存治疗肿瘤“内虚学说”初探[J].北京中医药,2011,30(3)：186-188.
8.何新慧,朱娇玉,吴中平.历代文献瘢瘕、积聚证治计算机分析[J].上海中医药杂志,2004,38(11)：62-64.
9.孙秉严,孙丽赢.孙秉严治癌40年经验集[M].北京：华龄出版社,1997：94-96.
10.张庆荣,刘畅,崔兴源.阳虚、阴虚慢性阻塞性肺疾病患者甲皱微循环和血液流变性变化的初步研究[J].辽宁中医杂志,1984,(2)：42.
11.叶雪清,杨少文,李安等.阳虚患者植物神经系统功能、甲皱微循环和血液流变学的改变及相互关系[J].中西医结合杂志,1989,(10)：618.
12.陈达理,周立红.脾气虚证患者纤溶、凝血、血小板活化指标的临床研究[J].中医杂志,2003,44(6)：453-455.
13.朱玲,周黎明,王正荣.参附注射液的作用及作用机制的研究进展[J].四川生理科学杂志,2004,26(2)：77-82.
14.梁桦,周桥灵,杨承祥等.参附注射液对妇科恶性肿瘤根治术患者围术期血液高黏滞和高凝状态的影响[J].广东医学,2013,34(11)：1747-1749.
15. Differding JA,Underwood SJ,Van PY, et al.First Place Resident's Competition:trauma induces a hypercoagulable state that is resistant to hypothermia as measured by thrombelastogram[J]. Am J Surg,2011,201(5):585-589.
16. Ruttmann TG,Lemmens HJ,Malott KA,et al.The haemodilution enhanced onset of coagulation as measured by the thrombelastogram is transient[J].Eur J Anaesthesiol,2006,23(7):574-579.
17. Bryan A,Gabriel Faz,Hatch,et al.Rapid Thrombelastography Delivers Real-Time Results That Predict Transfusion Within 1 Hour of Admission.TRAUMA Injury,Infection,and Critical Care,2011,71(2):407-417.
18. Karoutsos S,Nathan N,Lahrimi A,et al.Thrombelastogram reveals hypercoagulability after administration of gelatin solution[J]. Br J Anaesth,1999,82(2):175-177.
19. Hobson AR,Agarwala RA,Swallow RA,et al.Thrombelastography: current clinical applications and its potential role in interventional cardiology.Platelets,2006,17(8): 509-518.
20.徐志红,胡家安,权薇薇等.血栓弹力图评价老年冠心病合并睡眠呼吸暂停综合征患者高凝状态的临床价值[J].血栓与止血学,2012,18(3)：112-119.
21.何银华,李飞.急性脑梗死患者血栓弹力图临床研究[J].检验医学,2011,26(3)：163-165.
22. Bryan A,Kristin M,Zayde A,et al.Admission rapid thrombelastography predicts development of pulmonary embolism in trauma patients.J Trauma Acute Care Surg,2012,72(6):1470-1477.
23. Piccioli A,Prandoni P, Ewenstein BM, et al. Cancer and venous thromboembolism [J].AmHeartJ,1996,132(4):850-855.
24. Donati MB,Falanga A,Consonni R,etal.Cancer precoagulant in acute nonlymphoid leukemia:Relationship of enzyme detection to disease activity.Thromb Haemost,1990,64(1):11-16.
25.陆化.恶性肿瘤与血栓形成[J].医学综述.2001,7(8)：524-526.
26.金莉.血液高凝状态血小板与恶性肿瘤及其转移关系[J].实用癌症杂志.2003,18(5)：559.
27. Lopez JA,Kearon C,Lee AY Y. Deep venous thrombosis[M].Am Soc Hematol Educationnal Book,2004,439-456.
28. Otten HM,Mathijssen J,Cate HT,et al.Symptomatic venous thromboembosis in cancer Patients treated with chemotherapy:An underestimated Phenomenon[J].Arch Inter Med,2004,164(2):190-194.
29. VersoM,Agnelli G.Venous thromboembolism associated with longterm use of central venous catheters in cancer Patients[J].J Clin Oncol,2003,21(19):3665-3675.
30.郭德煌.恶性肿瘤的血液流变性[J].微循环学杂志,1997,7(2)：24.
31.蔺索琴,李爱筠,庄小玲等.恶性肿瘤、高血压病患者及健康人的血液流变学观察[J].肿瘤研究与临床,1999,11(6)：386.
32.王凤玲,黄佳滨,蔡栋梁,石昌国.肺癌患者凝血功能变化分析[J].浙江中西医结合杂志.2006,16(11)：683-684.
33.林粤.恶性肿瘤患者凝血指标测定的临床评价[J].现代中西医结合杂志.2006,15(5)：636-637.
34. Khorana AA,Ahrendt SA, Ryan CK,et al.Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res,2007,13(10):2870-2875.
35. Tetzlaff ED,Correa AM,Baker J, et al.The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma.Cancer,2007,109(10):1989-1995.
36.向祺,刘敏娟.肺癌和卵巢癌患者血栓相关标志物的实验研究.2010,16(1)：27-29.
37.周羽,向启云.血小板与恶性肿瘤及其转移的关系[J].临床血液学志,2010,23(6)：343-344.
38.李斌,罗建远.血小板参数在恶性肿瘤中变化的临床意义.卫生职业教育,2007,25(11)：150-151.
39. Jeffry L,Ernest E,Allison Sabel,et al.Rapid thrombelastography (r-TEG) identifies hypercosguhbility and predicts thromboembolic evens in surgical patients. Surgery,2009,146(4):764-774.
40. Ay C, Simanek R, Vormittag R,et al.High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients:Results from the Vienna Cancer and Thrombosis Study (CATS). Blood,2008,112(7):2703-2708.
41. Auwerda JJ, Yuana Y, Osanto S,et al.Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.Thromb Haemost, 2010,105(1):14-20.
42. Lebeau B,Chastang C, Brechot JM,et al.Subcutaneous Heparin Treatment Inereases Suruival in Small Cell Lung Cancer [J].Cance,1994,74:38.
43. Levine M,Hirsh J,Gent M,etal.Double blind randomized trial of very-low-dose warfarin for the Prevention of thronboembolism in stage IV breast cancer [J]. Lancet,1994,343:886-889.
44.严常开,刘惟莞.丹参素胶囊活血化瘀作用的实验研究[J].中成药,2003,25(8)：637-639.
45.姜开余,顾振伦.丹参素对CDllb. P-selectin、ICAM-1、VCAM-1、E-selectin表达的影响[J].中国药理学通报,2000,16(6)：682-685.
46.樊淑梅,任宝军,翟英姬.丹参注射液对胃癌术后患者血液高凝状态的影响[J].Chinese Journal of New Drugs,2012,21(21):2535-2538.
47.崔巍,精世杰,藤静茹等.活血化瘀中药抑制肿瘤细胞—血小板聚集的实验研究[J].中国中医基础医学杂志,1997,3(1)：27-28,31.
48.冯婧,田菲.川芎嗪注射液改善恶性肿瘤患者血液高凝状态60例临床观察[J].山西中医学院学报,2010,11(5)：24-25.
49.张红,王靖,张志芳.血府逐瘀汤加味治疗中晚期非小细胞肺癌血瘀证临床疗效及血流变指标观察[J]Clinical Journal of Chinese Medicine,2012,4(14):8-11.
50.迟惠昌,胡凤山,张青等.益气活血中药配合化学药物治疗晚期胃癌疗效观察[J].中华中医药杂志,2011,26(8)：1888-1890.
51.胡艳,侯安继,周莉,俞雷.益气活血方对中晚期非小细胞肺癌高凝状态作用的临床研究[J].辽宁中医杂志,2011,38(12)：2330-2332.
52.朱凯,潘迎英,杨怡敏.益气活血方对恶性肿瘤血瘀证的影响研究[J].实用中医杂志,2012,28(2)：90.
53.毕宏观,王俊茄,张柯楠等.参麦注射液对恶性肿瘤患者血液流变性及微循环的影响[J].中国医学物理学杂志,2005,22(5)：675-676.
54.刘展华.中医肿瘤学家周岱翰教授学术思想临床经验研究.博士,广州中医药,2011.
55.乔占兵,尹婷,李忠.王沛教授肿瘤论治及用药规律初探[J].中国临床医生,2003,33(4)：52-55.
56.王振华.孙桂芝教授关于肿瘤学术思想初探[J].中华中医药杂志,2009,24(7)：891-894.
57.沈霖,杨艳萍.朱曾柏教授治疗恶性肿瘤经验[J].新中医,1989,4：19-21.
58.曹利平,王向阳,苗文红等.谢远明临证思辨特点[J].陕西中医,2007,28(12)：1659-1661.
59.赵凤达.洪广祥治疗晚期肺癌的经验[J].新中医,1996(3)：3-4.
60.高振华.孙秉严论治肿瘤学术思想刍谈[J].中医研究,2009,22(1)：53-55.
61.李忠,刘丹,刘杰等.肿瘤中医“耗散病机假说”的建立和固摄法的提出.南京中医药大学学报,2006,22(3)：140-142.
1.孙秉严,孙丽赢.孙秉严治癌40例经验集.北京：华龄出版社,1997.
2.伍耀衡.温肾祛淤治疗恶性肿瘤探讨.河北中医,1997,19(4)：39-41.
3.张波,沈敏鹤,阮善明等.扶正为主,益气温阳为先沈敏鹤诊治肿瘤的经验探究[J].浙江中医药大学学报,2012,36(10)：1086-1088.
4.曾水成.肝癌的中医诊治再思考.中医研究,1997,10(6)：5-7.
5.李世辉.参附注射液对SP2/0骨髓瘤细胞作用的实验观察及其机制的初步探讨[J].中华实用中西医杂志,2005,18(18)：1045-1046.
6.伍耀衡,宁异真,许建邦等.参附注射液、高乌甲素注射液诱导白血病细胞株HL-60分化、凋亡的研究[J].广州中医药大学学报,2008,25(2)：131-137.
7.荣震,莫春梅.参附注射液择时治疗老年晚期非小细胞肺癌疗效观察[J].2008,35(3)：396-397.
8.周朝辉,章谙鸣.参附注射液治疗老年晚期非小细胞肺癌60例临床疗效观察[J].江西中医药,2004(04)：34.
9.赵丽红.刘嘉湘用温补治疗肿瘤经验[J].黑龙江中医药,1993(5)：4-6.
10.施志明.专家门诊录：温阳补肾治肺癌：随师临诊一得.上海中医药杂志,1990(11)：14-15.
11.郭骏琪.名老中医石玉林治疗乳腺癌骨转移30例.吉林中医药,1998,18(2)：3-4.
12.张丽娟.中西医结合治疗癌性胸腹腔积液36例[J].国医论坛,2001,16(2)：39-40.
13.张勤.中西医结合治疗癌性胸腹腔积液40例[J].河南中医,2013,33(6)：945-946.
14.谢安卫,韩俊.益气温阳汤治疗肿瘤化疗引起白细胞减少临床研究[J].辽宁中医药大学学报,2010,12(1)：140-141.
15.张爱萍,蔡焦生,范红燕等.益气温阳方治疗癌性发热46例[J].中国民间疗法,2011,19(5)：39-40.
16.张侠,刘端祺,刘彦珠.温阳散结中药对裸鼠移植性肝癌生长及微血管密度的影响.中国药学杂志,2000,35(4)：297.
2. Michelson AD.Methods for the measurement of platelet function[J].Am J Cardiol,2009,103(3 Suppl):20-26.
3. Bischof D,Dalbert S,Zollinger A,et al.Thrombelastography in the surgical patient[J].Minerva Anestesiol,2010,76(2):131-137.
4. Ganter MT,Hofer CK.Coagulation monitoring: current techniques and clinical use of viscoelastic point of care coagulation devices[J].Anesth Analg,2008,106(5):1366-1375.
5. Brohi K,Cohen MJ,Ganter MT,et al.Acute coagulopathy of trauma:hypoperfusion induces systemic anticoagulation and hyperfibrinolysis[J].J Trauma,2008,64(5):1211-1217.
6. Niles SE,Melaughlin DF,Perkins JG,et al.Increased Mortality associated with the early coagulopathy of traum in combat casualties[J].J Trauma,2008,64(6):1459-1463.
7. Kaufmann CR,Dwer KM,John D,et al.Usefulness of thembelastography in assessment of trauma patient coagulation[J].J Trauma, 1997,42(4):716-720.
8. Lier H,Krep H,Schochl H.Coagulatlon management in the treatment Of multiple trauma[J]. Anaesthesist,2009,58(10):1010-1026.
9. Stahel PF,Moore EE,Schreier SL,et al.Transfusion state Gies in pose injury coagulopathy[J].Curt Opin AnaesthesioL,2009,22:289-298.
10. Carroll RC,Craft RM,Langdon RJ,et al.Early evaluation of acute traumatic coagulopathy by thrombehstogmphy[J].Translational Research,2009,154(1):34-39.
11.Schreiber MA,Differding J,Thorborg P, et al.Hypercoagulability is most prevalent early after injury and in female patients[J].Trauma,2005,58(3):475-480.
12.蔡海英,叶立刚,徐善祥等.血栓弹力图在严重多发伤患者中的初步应用[J].中华创伤杂志,2011,27(12)：1115-1117.
13. Jeffry L,Ernest E,Michael Sawyer,et al.Primary Fibrinolysis Is Integral in the Pathogenesis of the Acute Coagulopathy of Trauma[J]. Annals ofSurgery,2010,252(3)：434-444.
14. Michael Nekludov,Bo Michael Bellander,Margareta Blomb,et al.Platelet Dysfunction in Patients with Severe Traumatic Brain Injury[J].NEUROTRAUMA,2007,24:1699-1706.
15. Max V Wohlauer,Ernest E Moore,Scott Thomas,et al.Early Platelet Dysfunction: An Unrecognized Role in the Acute Coagulopathy of Trauma[J].Am Coll Surg,2012,01(50):739-746.
16. Levrat A,Gros A,Rugeri L,et al.Evaluation of rotation thrombelastography for the diagnosis of hypefibrinolysis in trauma patients[J].Br J Anaesth,2008,100(6):792-797.
17. Brenni M,Wom M,Brueseh M,et al.Suecessful rotational thromboelastometry guided treatment of traumatic haemorrhage hypefibrinolysis and coagulopathy [J].Acta Anaesthesiol Seand,2010,54(1):111-117.
18. Johansson PI,Stensballe J. Effect of Haemostatic Control Resuscitation on mortality in massively bleeding patients:a before and after study[J]. Vox Sang,2009,96(2):111-118.
19. Bryan A,Gabriel Faz,Hatch,et al.Rapid Thrombelastography Delivers Real-Time Results That Predict Transfusion Within 1 Hour of Admission[J]. J Trauma Injury,Infection,and Critical Care,2011,71 (2):407-417.
20. Victor Jeger,Aristomenis K.Can Rapid TEG Accelerate the Search for Coagulopathies in the Patient With Multiple Injuries[J].TRAUMA-Injury,Infection, and Critical Care,2009,66(4):1253-1257.
21. Victor Jeger,Sandra Willi,Tun Liu,et al.The Rapid TEG a-Angle May Be a Sensitive Predictor of Transfusion in Moderately Injured Blunt Trauma Patients[J].The Scientific World Journal,2012:821794.
22. Wilson D,Cooke EA,McNatly MA,et al.Changes in coagulability as measured by thrombelastography following surgery for proximal femoral fracture[J].Injury,2001,32(10):765-770.
23. Bryan A,Kristin M,Zayde A,et al.Admission rapid thrombelastography predicts development of pulmonary embolism in trauma patients[J].J Trauma Acute Care Surg,2012,72(6):1470-1477.
24.彭南海,叶向红,陈月英.凝血功能监测预防腹部创伤术后深静脉血栓的护理研究[J].护理学杂志,2013,28(8)：65-67.
25. Jeffry L,Ernest E,Allison Sabel,et al.Rapid thrombelastography(r-TEG) identifies hypercosguhbility and predicts thromboembolic evens in surgical patients[J].Surgery,2009,146(4):764-774.
26. Senzolo M,Agarwal S,Zappoli P, et al.Heparin-like effect contributes to the coagulopathy in patients with acute liver failure undergoing liver transplantation [J]. Liver Int,2009,29(5):754-759.
27. Agarwal S,Senzolo M,Melikian C,et al.The prevalence of a heparinlike effect shown on the thromboelastograph in patients undergoing liver transplantation[J]. Liver Transpl,2008,14(6):855-860.
28. Kang YG,Martin OJ,Marquez J,et al.Intraoperative changes in blood coagulation and thromboelastographic monitoring in liver transplantation[J].Anesth Analg,1985,64:888.
29. de Pietri L,Masetti M,Montalti R,et al.Use of recombinant factor IX and thromboelastography in a patient with hemophilia B undergoing liver transplantation: a case report[J].Transplant Proc,2008,40(6):2077-2079.
30.寇建涛,樊华,李立新等.血栓弹力图在终末期肝硬化肝移植患者围手术期的应用(附27例报告)[J].器官移植,2011,2(6)：310-313.
31. Whitson BA,HuD-Dleston SJ,Savik K,et al.Bloodless cardiac surgery is associated with decreased morbidity and mortality[J].J Card Surg,2007,22(5):373-378.
32. Ak K,Isbir CS,Tetik S,et al.Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG:a prospective randomized study[J].J Card Surg,2009,24(4):404-410.
33.杨丽君,林茹,叶莉芬等.血栓弹力图在小儿体外循环围术期的应用价值[J].中国体外循环杂志,2013,11(1)：11-14.
34. Kenneth J, Tuman MD, Robert J, et al.Evalution of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelatographic assay[J].J Cardiothroac Vasc Anesth,1994,8:144-149.
35. Artang R,Frandsen NJ,Nielsen JD.Application of basic and composite thrombelastography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin:an in vivo study[J]. Thromb J,2009,7(1):14.
36.纪宏文,马丽,高旭蓉等.血栓弹力图在体外循环心血管手术的应用[J].中国体外循环杂志,2011,9(3)：170-172.
37. Cosmi B,Alatri A,Cattaneo M, et al.Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures:guidelines of the Italian society for haemostasis and thrombosis (SISET)[J].Thromb Res,2009,124(5):6-12.
38. Westbrook AJ,Olsen J,Bailey M,et al.Protocol based on thromboelastograph(TEG) out-performs physician preference using laboratory coagulation tests to guide blood replacement during and after cardiac surgery:a pilot study [J]. Heart Lung Circ,2009,18(4):277-288.
39. Taneja R,Fernandes P,Marwaha G,et al.Perioperative coagulation management and blood conservation in cardiac surgery:a canadian survey [J].J Cardiothorac Vasc Anesth,2008,22(5):662-669.
40. Differding JA,Underwood SJ,Van PY, et al.First Place Resident's Competition:trauma induces a hypercoagulable state that is resistant to hypothermia as measured by thrombelastogram[J].Am J Surg,2011,201(5):585-589.
41.Ruttmann TG,Lemmens HJ,Malott KA,et al.The haemodilution enhanced onset of coagulation as measured by the thrombelastogram is transient[J].Eur J Anaesthesiol,2006,23(7):574-579.
42. Karoutsos S,Nathan N,Lahrimi A,et al.Thrombelastogram reveals hypercoagulability after administration of gelatin solution[J].Br J Anaesth,1999,82(2):175-177.
43. Hobson AR,Agarwala RA,Swallow RA,et al.Thrombelastography:current clinical applications and its potential role in interventional cardiology. Platelets,2006,17(8):509-518.
44.徐志红,胡家安,权薇薇等.血栓弹力图评价老年冠心病合并睡眠呼吸暂停综合征患者高凝状态的临床价值[J].血栓与止血学,2012,18(3)：112-119.
45.何银华,李飞.急性脑梗死患者血栓弹力图临床研究[J].检验医学,2011,26(3)：163-165.
46.肖莉,陈永武,谢俊刚.肺癌患者血栓弹力图检测的临床意义[J].肿瘤防治研究,2000,27(3)：213-214.
47.王莉,裴文仲,杨建东等.血栓弹力图在恶性肿瘤高凝状态诊断中的应用价值[J].实用临床医药杂志,2013,17(11)：119-121.
48. Chen A,Teruya J.Global hemostasis testing thromboelastography:old echnology,new applications[J].Clin Lab Med,2009,29(2):391-407.
49.龚波,俞菁,胡荷宇等.用血栓弹力图分析仪检测不同妊娠期孕妇的凝血功能[J].临床检验杂志,2012,30(6)：475-476.
50. Sharma SK,Philip J,Wiley J.Thromboelastographic changes in healthy parturients and postpartum women[J].Anesth Analg,1997,85(1):94-98.
51.章莉,俞菁,侯雅萍等.用血栓弹力图监测妊娠合并血小板减少症孕妇凝血功能[J].临床检验杂志,2013,31(7)：487-489.
52. Roeloffzen WW, Kluin-Nelemans HC,Mulder AB,et al.Thrombocytopenia affects plasmatic coagulation as measured by thrombelastography[J].Blood Coagul Fibrinolysis,2010,21 (5):389-397.
53. Slichter SJ.Relationship between platelet count and bleeding risk in thrombocytopenic patients[J].Trans Med Rev,2004,18(3):153-167.
54. Reikvam H,Steien E,Hauge B,et al.Thrombelastography[J].Trans Apher Sci,2009,40(2):119-123.
55.左艳,娄世锋,张颖等.血栓弹力图在重度血小板减少者中的应用[J].医学与临床,2011,8(16)：1931-1934.
56.黄晓英,韩旭东,王芳等.血栓弹力图评价肝病不同阶段凝血功能的改变[J].胃肠病学和肝病学杂志,2010,19(6)：537-539.
57.陈家华,廖建梅,殷建国等.血栓弹力图在肝硬化患者围术期的应用[J].江苏医药,2005,31(11)：827-829.
58.李存江,张石江,邵永丰等.肝素酶修正的血栓弹力图在冠脉搭桥术前的应用[J].江苏医药,2013,39(4)：438-440.
59.燕姿辰,杨新春,周丽娜.血栓弹力图评价肝素浓度变化对凝血功能影响的价值[J].山东医药,2012,52(31)：7.
60. MATZELLE SJ,GIBBS NM,WEIGHTMAN W, et al.Systemic anticoagulant effect of low-dose subcutaneous unfractionated heparin as determined using thrombelastography[J]. Anaesth Intensive Care.2007,35(4):498-504.
61.BOYCE H,HUME-SMITH H,NG J, et al.Use of thromboelastography to guide thromboprophylaxis after caesarean section[J].Int J Obstet Anesth,2011,20(3):213-218.
62. Mercedes P.Disseminated intravascular coagulation[J].ICS,2002,1237:163-168.
63.肖菲,金晓东,魏永刚等.血栓弹力图在诊断DIC中的价值探讨[J].四川大学学报：医学版,2008,39(3)：521-522.
64. Rasoul Ferasatkish,Hossein NaD-Dafnia,Seyed-Mostafa Alavi,et al.Diagnosis and Treatment of Disseminated Intravascular Coagulation:A Case Report.Arch Iranian Med,2007,10(3):404-408.
65.黄婷婷,任艺虹.血栓弹力图对弥漫性血管内凝血的诊疗价值.中华心血管病杂志,2011,5(39)：461.
66. Carroll RC,Worthington RE,Craft RM,et al.Post interventional cardiology urinary thromboxane correlates with platelet mapping detected aspirin resistance[J].Thromb Res,2010,125(4):e118-122.
67. Rivard GE,Brummel-Ziedins KE,Mann KG,et al.Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography[J].J Thromb Haemost,2005,3(9):2039-2043.
68. Bliden KP,Dichiara J,Tantry US,et al.Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? [J].J Am Coll Cardiol,2007,49(6):657-666.
69. Bochsen L,Wiinberg B,Kjelgaard-Hansen M,et al.Evaluation of the TEG platelet mapping assay in blood donors[J].Thromb J,2007,5:3.
70. Gurbel PA,Bliden KP,Hiatt BL,et al.Clopidogrel for coronary stenting: response variability, drug resistance,and the effect of pretreatment platelet reactivity [J].Circulation,2003,107(23):2908-2913.
71. Gurbel PA,Bliden KP,Guyer K,et al.Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting[J].Thromb Res,2007,119(5):563-570.
72. Gurbel PA,Bliden KP,Navickas IA,et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting is chemic events[J].Am Heart J,2010,160:346-354.
73. Swallow RA,Agarwala RA,Dawkins KD,et al.Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy[J].Platelets,2006,17(6):385-392.
74. Hobson AR,Petley GW,Dawkins KD,et al.A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography [J].Platelets,2007,18(7):497-505.
75.任艺虹,盖鲁粤,杨庭树等.改良血栓弹力图法和流式细胞测定技术对血小板活性抑制程度的比较研究[J].中华心血管病杂志,2007,35(4)：366-367.
76.王洪叶,唐发宽,肖军.冠状动脉支架术后发生再缺血事件与血小板活性有关[J].心脏杂志,2010,22(5)：F002.
77. Orlikowski CE,Rocke DA,Murray WB,et al.Thrombelastography changes in preeclampsia and eclampsia. Br J Anaesth,1996,77(2):157-161.
78. Dickinson KJ,Troxler M,Homer-Vanniasinkam S.The surgical application of point of care haemostasis and platelet function testing. Br J Surg,2008,95(11):1317-1330.
1. Elalamy I,Verdy E,Gerotziafas G,etal.Pathogenesis of venous thromboembolic disease in cancer[J]. Pathol Biol(Paris),2008,56(4):184-194.
2. Korte W. Cancer and thrombosis:An increasingly important association[J].Support Care Cancer,2008,16(3):223-228.
3.曹利平,王向阳,苗文红等.谢远明临证思辨特点[J].陕西中医,2007,28(12)：1659-1661.
4.赵凤达.洪广祥治疗晚期肺癌的经验[J].新中医,1996(3)：3-4.
5.唐武军,王笑民.郁仁存治疗肿瘤“内虚学说”初探[J].北京中医药,2011,30(3)：186-188.
6.沈霖,杨艳萍.朱曾柏教授治疗恶性肿瘤经验[J].新中医,1989,4：19-21.
7.王笑民,郁仁存,王禹堂等.晚期非小细胞肺癌患者气虚血瘀证的研究[J].中国中西医结合杂志,1994,14(12)：724-726.
8.司富春,侯红丽,刘瑜等.甲状腺肿瘤的中医证型和方药分析.中华中医药学会中医方证基础研究与临床应用学会研讨会论文集：197-203.
9.张娟,王鹏,刘鲁明.胰腺癌中医证候分析[J].中华中医药杂志,2012,27(3)：579-581.
10.汪天喜.恶性骨肿瘤围化疗期中医证候规范化初步研究.硕士,广州中医药大学.2009.
11.沈旭波,侯凤刚,刘庆.原发性肝癌1368例中医单证出现状况文献分析[J].中医药学刊,2004,22(1)：69-70.
12.王禹堂,王笑民,郁仁存.癌症患者的血瘀证研究[J].中国医药学报,1996,11(6)：57.
13.孙红,李萍萍.乳腺癌中医证候分类与预后相关性的初步研究[J].中国中医基础医学杂志,2003,9(2)：72-73.
14.李道睿,张培彤,胡晓梅等.300例中晚期原发性支气管肺癌血瘀证分布规律的调查研究[J].中国中医药信息杂志.2007,14(3)：19-21.
15.周阿高,丁红熊,陈梅芳等.140例胃部恶性肿瘤患者手术前后和死亡前血瘀证研究[J].中西医结合杂志,1990,10(9)：540-541.
16.朱建红,朱起贵.中医对微循环的若干认识[J].微循环杂志,2002,12(2)：41-43.
17.田牛,李玉珍,刘育英.血瘀证的微循环研究[J].中国中西医结合杂志,2001,21(4)：248-249.
18.田牛,等.微循环方法学[M].北京：原子能出版社,1987,5.
19.陈泽霖,等,舌诊研究[M].第二版.北京：上海科学技术出版社,1982,225.
20.陆远志.微循环基础与临床[M].北京：人民军医出版社,1986：269.
21.魏艾红.自血病舌质及血疲病理研究[J].中国医药学报,1995,10(5)：11.
22.陈泽民,李泽浩,江建平等.肝癌病人舌质与微循环的关系—附100例临床分析[J].中西医结合肝病杂志,1999,9(3)：44-45.
23.万晓燕,任东峰.桃红四物汤加味配合功能锻炼治疗乳腺癌术后上肢肿胀21例[J].吉林中医药,2007,27(11)：30.
24.张传芳.恶性肿瘤患者临床与血液黏度变化探讨[J].中国现代医学杂志,2004,14(7)：73-78.
25.胡庆福,陈泽霖,陈依萍等.血瘀型恶性肿瘤病人红细胞膜流动性及血液流变性的观察[J].肿瘤,1990,(7)：10.
26.翁维良,崔晶,王怡.冠心病心绞痛患者259例血液粘度测定[J].中华心血管病杂志,1984,12(3)：183.
27.翁维良.脑血栓血瘀证患者红细胞变形性等客观检测指标的探讨[J].中西医结合杂志,1988,8(7)：424.
28.须惠仁,傅湘琦,向丽华等.肝郁证的动物实验研究—激怒刺激对大白鼠血液流变学的影响[J].中医杂志,1991,32(6)：44-46.
29.丘瑞香,罗致强,朱雅宜等.冠心病血瘀证血液理化特性与中医证型相关性研究[J].中医杂志,2002,43(5)：378-379.
30.叶兴涛.肺癌瘀血舌质与血液流变学变化的相关性分析[J].中国中医药科技,2012,19(3)：196-197.
31.富琦,张晨曦,杨国旺等.恶性肿瘤患者凝血指标临床分析及其与血瘀证的相关性[J].中医杂志,2011,52(23)：2024-2030.
32.李晓惠,张文曦,倪海雯.恶性血液病血瘀证的研究[J].南京中医药大学学报(自然科学版),2000,16(3)：146-147.
33.刘永惠,杨晓峰,周冬枝.肿瘤血瘀证实质及活血化瘀治则的研究[J].河北中医,2002,24(4)：252-254.
34.王缨,李国贤.慢性肾衰竭患者血液流变学指标及血液粘滞综合征与血瘀证关系的研究[J].中国中西医结合肾病杂志,2003,4(2)：92-95.
35.李晓明.肾脏病血瘀证患者血浆内皮素Q颗粒膜蛋白140含量测定的意义[J].中国中医基础医学杂志,1996,2(5)：35.
36.施赛珠,石志芸,陈剑秋等.血瘀证与血小板活化的关连研究[J].中国中医基础医学杂志,1996,2(4)：22.
37.石志芸,李晓明,陈剑秋.血小板Q颗粒膜蛋白140检测在“病”与“证”的特异性联系[J].中国中医基础医学杂志,1997,3(1)：35.
38.陈永斌,阮玉山,黄李平等.脑挫裂伤血瘀证患者血小板活化分子CD62P和TSP的改变及临床意义[J].广西医科大学学报,2007,24(2)：192-194.
39.徐西,廖家帧,王硕仁等.310例血瘀证患者血小板功能与中医辨证关系的临床研究[J].中国中西医结合杂志,1993,13(12)：718-722.
40.叶向荣,张素芬.益气活血与理气活血对血瘀证大鼠血小板5-轻色胺、丙二醛和血浆血 栓素及6-酮-前列腺素的影响[J].山东中医药大学学报,1997,21(1)：76-77.
41.蓝肇熙,李薇,张进陶等.损伤血瘀证中PAF变化及桃红四物汤对其干预的实验研究[J].四川中医,2007,25(10)：9-11.
42.陈利国,孙兆贵,王蕾等.血瘀证与血管内皮细胞内游离钙浓度关系的实验研究[J].山东中医药大学学报,2001,25(1)：55-57.
43.陈利国,陈畅宏,屈援等.血府逐瘀汤对血瘀证大鼠血管内皮细胞黏附分子表达的影响[J].山东中医药大学学报,2006,30(5)：395-398.
44.黄敏,谢建祥,吴锐等.血瘀证目征与血管内皮细胞损伤的关系[J].中华中医药杂志,2011,26(4)：781-784.
45.江欢,周岩,孙晓红等.中医“热毒血瘀证”模型大鼠血管内皮损伤及血小板功能障碍研究[J].中西医结合心脑血管病杂志,2009,7(4)：425-428.
46.罗晓琴,徐咏梅,唐勇等.从肿瘤转移相关因子探讨非小细胞肺癌气虚血瘀证的病理基础[J].中国中西医结合杂志,2009,29(10)：886-888.
47.王奇,陈云波,赖世隆等.血府逐瘀汤对用血瘀证兔血清损伤的血管内皮细胞的形态学影响[J].广州中医药大学学报,2001,18(2).105-109.
48.王奇,陈云波,赖世隆等.血府逐瘀汤对血瘀证兔模型血清损伤的血管内皮细胞内分泌功能的影响[J].中国实验方剂学杂志,2002,8(2).12-14.
49.蔡钦朝,汪琼华,吴云智等.血瘀证患者血管内皮内分泌功能的观察.安徽中医学院学报,1998,17(2)：61-63.
50.崔同建,陈香莲,蒋云林等.复发转移大肠癌血瘀证与外周血PTEN、CD44基因表达相关性分析[J].福建中医药大学学报,2011,21(4)：1-4.
51.崔同建,陈香莲,蒋云林等.晚期大肠癌的病性证素与外周血p53、nm23的相关性研究[J].现代消化及介入诊疗,2011,16(4)：235-238.
52.陈怡宏.胃癌血瘀证基因表达及细胞信号信道蛋白表达的研究.广州中医药大学,硕士,2002.
53.姜林.胃癌血瘀证与p53、C-erbB-2、VEGF表达的相关性研究.湖北中医学院,硕士,2008.
54.吴朝泰.血瘀证与胃癌及癌前期病变肿瘤相关基因表达的关系.广州中医药大学,硕士,2000.
55.赵海燕,屠德敬,夏溪等.6例姑息治疗期大肠癌血瘀证血清蛋白质组学探索性研究[J].中华中医药学刊,2012,30(8)：1777-1779.
56.李雪梅,许玥,林华胜等.中晚期非小细胞肺癌MGMT基因甲基化表达与中医证型的相关性研究[J].四川中医,2012,30(5)：36-38.
57. Caine GJ,Stonelake PS.Lip GY The hypereoagulable state of malignaney:pathogenesis and eurrent debate[J].Neophlasia,2002,4(6):465-473.
58. Lopez JA,Kearon C,LeeAYY. Deepvenous thrombosis[M].Am Soc Hematol Educationnal Book,2004,439-456.
59. Otten HM,Mathijssen J,Cate HT,et al.Symptomatic venous thromboembosis in cancer Patients treated with chemotherapy:An underestimated Phenomenon[J].Arch Inter Med,2004,164(2):190-194.
60. VersoM,Agnelli G.Venous thromboembolism associated with longterm use of central venous catheters in cancer Patients[J].J Clin Oncol,2003,21(19):3665-3675.
61.孙校男,郭勇.大肠癌辅助化疗期血瘀证血清蛋白质组学探究[J].中华中医药学刊,2013,31(5)：1081-1084.
62.金伟,哈木拉提·吾甫尔等.恶性肿瘤血瘀证型血栓前状态分子标志物测定及其意义[J].Chinese Journal of Information on TCM,2009,16(10):18-21.
63.蒋霆辉,陈越,潘龙赐等.晚期恶性肿瘤患者血栓前状态检测指标与中医证型的相关性研究[J].上海中医药大学学报,2010,24(2)：31-33.
64.张乐,王彬彬,舒琦瑾.大肠癌临床分期及中医证型与血浆D-二聚体的相关性研究[J].浙江中医杂志,2010,45(2)：96-97.
65.严常开,刘惟莞.丹参素胶囊活血化瘀作用的实验研究[J].中成药,2003,25(8)：637-639.
66.姜开余,顾振伦.丹参素对CDllb. P-selectin. ICAM-1、VCAM-1、E-selectin表达的影响[J].中国药理学通报,2000,16(6)：682-685.
67.樊淑梅,任宝军,翟英姬.丹参注射液对胃癌术后患者血液高凝状态的影响[J]Chinese Journal of New Drugs,2012,21(21):2535-2538.
68.刘锦蓉,叶松柏.川芎嗪抗肿瘤转移作用及其机理[J].中国药理学与毒理学杂志,1993,7(2)：149-152.
69.王生,赵杨,陶丽等.川芎嗪对肿瘤介导的血液高凝的影响中国[J].中国药理学通报,2012,28(5)：709-715.
70.冯婧,田菲.川芎嗪注射液改善恶性肿瘤患者血液高凝状态60例临床观察[J].山西中医学院学报,2010,11(5)：24-25.
71.李麒,陈泽涛.活血化瘀法改善原发性支气管肺癌高凝状态临床观察[J].辽宁中医药大学学报,2013,15(8)：182-185.
72.胡国志,武英蕾等.金龙胶囊改善恶性肿瘤化疗患者高凝状态的临床分析[J].中国肿瘤临床,2012,39(22)：1846-1848.
73.李春越.血瘀证及活血化瘀方药研究进展[J].中西医结合杂志,1988,8(5)：317-320.
74.白刚,肖供彬.中药方剂研究与应用大全[M].北京：中国科学技术出版社,1995：43.
75.王阶,荆鲁等.血府逐瘀汤拆方临床研究[J].中国中药杂志,2004,29(8)：803-806.
76.张红,王靖,张志芳.血府逐瘀汤加味治疗中晚期非小细胞肺癌血瘀证临床疗效及血流变指标观察[J]Clinical Journal of Chinese Medicine,2012,4(14):8-11.
77.李莉芳.杏丁注射液治疗急性脑梗死30例临床分析[J].北京中医药,2008,27(5)：365-367.
78.刘建德.杏丁注射液对肺癌患者高凝血状态的影响[J].当代医学,2008,14(22)：150-151.
79.魏里平,姜海量,王来界.水蛭素的药理作用中国中医基础研究杂志,2004,15(8)：236-239.
80.唐莉,段巧虹,范平生.水蛭治疗恶性肿瘤高凝状态临床研究[J].中医药临床杂志,2012,24(9)：871-872.
81.崔巍,精世杰,藤静茹等.活血化瘀中药抑制肿瘤细胞—血小板聚集的实验研究[J].中国中医基础医学杂志,1997,3(1)：27-28,31.
82.姜林,孔庆志.活血化瘀药抗肿瘤作用的实验研究概况[J].湖北中医杂志,2008,30(8)：63.
83.迟惠昌,胡凤山,张青等.益气活血中药配合化学药物治疗晚期胃癌疗效观察[J].中华中医药杂志,2011,26(8)：1888-1890.
84.胡艳,侯安继,周莉,俞雷.益气活血方对中晚期非小细胞肺癌高凝状态作用的临床研究[J].辽宁中医杂志,2011,38(12)：2330-2332.
85.邓生明,陆用莲,林小清.益气活血方对中晚期非小细胞肺癌高凝状态作用运用分析[J].Clinical Journal of Chinese Medicine,2012,4(18):74-75.
86.朱凯,潘迎英,杨怡敏.益气活血方对恶性肿瘤血瘀证的影响研究[J].实用中医杂志,2012,28(2)：90.
87.王炳胜,张秀丽,王涛等.益气活血中药治疗恶性肿瘤高纤维蛋白原血症疗效观察[J].中国中医急症,2003,12(6)：517-518.
88.毕宏观,王俊茄,张柯楠等.参麦注射液对恶性肿瘤患者血液流变性及微循环的影响[J].中国医学物理学杂志,2005,22(5)：675-676.
89.朱玲,周黎明,王正荣.参附注射液的作用及作用机制的研究进展[J].四川生理科学杂志,2004,26(2)：77-82.
90.梁桦,周桥灵,杨承祥等.参附注射液对妇科恶性肿瘤根治术患者围术期血液高黏滞和高凝状态的影响[J].广东医学,2013,34(11)：1747-1749.
1. Korte W. Cancer and thrombosis:An increasingly important association[J].Support Care Cancer, 2008,16(3):223-228.
2. Farge D, Durant C,Villiers S,et al.Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients [J].Thromb Res,2010,125(Supp12):S108-116.
3. Elalamy I,Verdy E,Gerotziafas G,et al. Pathogenesis of venous thromboembolic disease in cancer [J].Pathol Biol(Paris),2008,56(4):184-194.
4.林胜友,沈敏鹤,舒静娜等.780例大肠癌中医证型分类特征的回顾性分析[J].浙江中医药大学学报,2011,35(3)：322-324.
5.黎敬波,张征,林丽珠,等.非小细胞肺癌417例证候分布的临床研究[J].广州中医药大学学报,2009,26(1)：73-77.
6.孙建立,李春杰,李和根等.刘嘉湘扶正法治癌学术思想介绍[J].当代名医,2006,47(11)：814-816.
7.唐武军,王笑民.郁仁存治疗肿瘤“内虚学说”初探[J].北京中医药,2011,30(3)：186-188.
8.何新慧,朱娇玉,吴中平.历代文献瘢瘕、积聚证治计算机分析[J].上海中医药杂志,2004,38(11)：62-64.
9.孙秉严,孙丽赢.孙秉严治癌40年经验集[M].北京：华龄出版社,1997：94-96.
10.张庆荣,刘畅,崔兴源.阳虚、阴虚慢性阻塞性肺疾病患者甲皱微循环和血液流变性变化的初步研究[J].辽宁中医杂志,1984,(2)：42.
11.叶雪清,杨少文,李安等.阳虚患者植物神经系统功能、甲皱微循环和血液流变学的改变及相互关系[J].中西医结合杂志,1989,(10)：618.
12.陈达理,周立红.脾气虚证患者纤溶、凝血、血小板活化指标的临床研究[J].中医杂志,2003,44(6)：453-455.
13.朱玲,周黎明,王正荣.参附注射液的作用及作用机制的研究进展[J].四川生理科学杂志,2004,26(2)：77-82.
14.梁桦,周桥灵,杨承祥等.参附注射液对妇科恶性肿瘤根治术患者围术期血液高黏滞和高凝状态的影响[J].广东医学,2013,34(11)：1747-1749.
15. Differding JA,Underwood SJ,Van PY, et al.First Place Resident's Competition:trauma induces a hypercoagulable state that is resistant to hypothermia as measured by thrombelastogram[J]. Am J Surg,2011,201(5):585-589.
16. Ruttmann TG,Lemmens HJ,Malott KA,et al.The haemodilution enhanced onset of coagulation as measured by the thrombelastogram is transient[J].Eur J Anaesthesiol,2006,23(7):574-579.
17. Bryan A,Gabriel Faz,Hatch,et al.Rapid Thrombelastography Delivers Real-Time Results That Predict Transfusion Within 1 Hour of Admission.TRAUMA Injury,Infection,and Critical Care,2011,71(2):407-417.
18. Karoutsos S,Nathan N,Lahrimi A,et al.Thrombelastogram reveals hypercoagulability after administration of gelatin solution[J]. Br J Anaesth,1999,82(2):175-177.
19. Hobson AR,Agarwala RA,Swallow RA,et al.Thrombelastography: current clinical applications and its potential role in interventional cardiology.Platelets,2006,17(8): 509-518.
20.徐志红,胡家安,权薇薇等.血栓弹力图评价老年冠心病合并睡眠呼吸暂停综合征患者高凝状态的临床价值[J].血栓与止血学,2012,18(3)：112-119.
21.何银华,李飞.急性脑梗死患者血栓弹力图临床研究[J].检验医学,2011,26(3)：163-165.
22. Bryan A,Kristin M,Zayde A,et al.Admission rapid thrombelastography predicts development of pulmonary embolism in trauma patients.J Trauma Acute Care Surg,2012,72(6):1470-1477.
23. Piccioli A,Prandoni P, Ewenstein BM, et al. Cancer and venous thromboembolism [J].AmHeartJ,1996,132(4):850-855.
24. Donati MB,Falanga A,Consonni R,etal.Cancer precoagulant in acute nonlymphoid leukemia:Relationship of enzyme detection to disease activity.Thromb Haemost,1990,64(1):11-16.
25.陆化.恶性肿瘤与血栓形成[J].医学综述.2001,7(8)：524-526.
26.金莉.血液高凝状态血小板与恶性肿瘤及其转移关系[J].实用癌症杂志.2003,18(5)：559.
27. Lopez JA,Kearon C,Lee AY Y. Deep venous thrombosis[M].Am Soc Hematol Educationnal Book,2004,439-456.
28. Otten HM,Mathijssen J,Cate HT,et al.Symptomatic venous thromboembosis in cancer Patients treated with chemotherapy:An underestimated Phenomenon[J].Arch Inter Med,2004,164(2):190-194.
29. VersoM,Agnelli G.Venous thromboembolism associated with longterm use of central venous catheters in cancer Patients[J].J Clin Oncol,2003,21(19):3665-3675.
30.郭德煌.恶性肿瘤的血液流变性[J].微循环学杂志,1997,7(2)：24.
31.蔺索琴,李爱筠,庄小玲等.恶性肿瘤、高血压病患者及健康人的血液流变学观察[J].肿瘤研究与临床,1999,11(6)：386.
32.王凤玲,黄佳滨,蔡栋梁,石昌国.肺癌患者凝血功能变化分析[J].浙江中西医结合杂志.2006,16(11)：683-684.
33.林粤.恶性肿瘤患者凝血指标测定的临床评价[J].现代中西医结合杂志.2006,15(5)：636-637.
34. Khorana AA,Ahrendt SA, Ryan CK,et al.Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res,2007,13(10):2870-2875.
35. Tetzlaff ED,Correa AM,Baker J, et al.The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma.Cancer,2007,109(10):1989-1995.
36.向祺,刘敏娟.肺癌和卵巢癌患者血栓相关标志物的实验研究.2010,16(1)：27-29.
37.周羽,向启云.血小板与恶性肿瘤及其转移的关系[J].临床血液学志,2010,23(6)：343-344.
38.李斌,罗建远.血小板参数在恶性肿瘤中变化的临床意义.卫生职业教育,2007,25(11)：150-151.
39. Jeffry L,Ernest E,Allison Sabel,et al.Rapid thrombelastography (r-TEG) identifies hypercosguhbility and predicts thromboembolic evens in surgical patients. Surgery,2009,146(4):764-774.
40. Ay C, Simanek R, Vormittag R,et al.High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients:Results from the Vienna Cancer and Thrombosis Study (CATS). Blood,2008,112(7):2703-2708.
41. Auwerda JJ, Yuana Y, Osanto S,et al.Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.Thromb Haemost, 2010,105(1):14-20.
42. Lebeau B,Chastang C, Brechot JM,et al.Subcutaneous Heparin Treatment Inereases Suruival in Small Cell Lung Cancer [J].Cance,1994,74:38.
43. Levine M,Hirsh J,Gent M,etal.Double blind randomized trial of very-low-dose warfarin for the Prevention of thronboembolism in stage IV breast cancer [J]. Lancet,1994,343:886-889.
44.严常开,刘惟莞.丹参素胶囊活血化瘀作用的实验研究[J].中成药,2003,25(8)：637-639.
45.姜开余,顾振伦.丹参素对CDllb. P-selectin、ICAM-1、VCAM-1、E-selectin表达的影响[J].中国药理学通报,2000,16(6)：682-685.
46.樊淑梅,任宝军,翟英姬.丹参注射液对胃癌术后患者血液高凝状态的影响[J].Chinese Journal of New Drugs,2012,21(21):2535-2538.
47.崔巍,精世杰,藤静茹等.活血化瘀中药抑制肿瘤细胞—血小板聚集的实验研究[J].中国中医基础医学杂志,1997,3(1)：27-28,31.
48.冯婧,田菲.川芎嗪注射液改善恶性肿瘤患者血液高凝状态60例临床观察[J].山西中医学院学报,2010,11(5)：24-25.
49.张红,王靖,张志芳.血府逐瘀汤加味治疗中晚期非小细胞肺癌血瘀证临床疗效及血流变指标观察[J]Clinical Journal of Chinese Medicine,2012,4(14):8-11.
50.迟惠昌,胡凤山,张青等.益气活血中药配合化学药物治疗晚期胃癌疗效观察[J].中华中医药杂志,2011,26(8)：1888-1890.
51.胡艳,侯安继,周莉,俞雷.益气活血方对中晚期非小细胞肺癌高凝状态作用的临床研究[J].辽宁中医杂志,2011,38(12)：2330-2332.
52.朱凯,潘迎英,杨怡敏.益气活血方对恶性肿瘤血瘀证的影响研究[J].实用中医杂志,2012,28(2)：90.
53.毕宏观,王俊茄,张柯楠等.参麦注射液对恶性肿瘤患者血液流变性及微循环的影响[J].中国医学物理学杂志,2005,22(5)：675-676.
54.刘展华.中医肿瘤学家周岱翰教授学术思想临床经验研究.博士,广州中医药,2011.
55.乔占兵,尹婷,李忠.王沛教授肿瘤论治及用药规律初探[J].中国临床医生,2003,33(4)：52-55.
56.王振华.孙桂芝教授关于肿瘤学术思想初探[J].中华中医药杂志,2009,24(7)：891-894.
57.沈霖,杨艳萍.朱曾柏教授治疗恶性肿瘤经验[J].新中医,1989,4：19-21.
58.曹利平,王向阳,苗文红等.谢远明临证思辨特点[J].陕西中医,2007,28(12)：1659-1661.
59.赵凤达.洪广祥治疗晚期肺癌的经验[J].新中医,1996(3)：3-4.
60.高振华.孙秉严论治肿瘤学术思想刍谈[J].中医研究,2009,22(1)：53-55.
61.李忠,刘丹,刘杰等.肿瘤中医“耗散病机假说”的建立和固摄法的提出.南京中医药大学学报,2006,22(3)：140-142.
1.孙秉严,孙丽赢.孙秉严治癌40例经验集.北京：华龄出版社,1997.
2.伍耀衡.温肾祛淤治疗恶性肿瘤探讨.河北中医,1997,19(4)：39-41.
3.张波,沈敏鹤,阮善明等.扶正为主,益气温阳为先沈敏鹤诊治肿瘤的经验探究[J].浙江中医药大学学报,2012,36(10)：1086-1088.
4.曾水成.肝癌的中医诊治再思考.中医研究,1997,10(6)：5-7.
5.李世辉.参附注射液对SP2/0骨髓瘤细胞作用的实验观察及其机制的初步探讨[J].中华实用中西医杂志,2005,18(18)：1045-1046.
6.伍耀衡,宁异真,许建邦等.参附注射液、高乌甲素注射液诱导白血病细胞株HL-60分化、凋亡的研究[J].广州中医药大学学报,2008,25(2)：131-137.
7.荣震,莫春梅.参附注射液择时治疗老年晚期非小细胞肺癌疗效观察[J].2008,35(3)：396-397.
8.周朝辉,章谙鸣.参附注射液治疗老年晚期非小细胞肺癌60例临床疗效观察[J].江西中医药,2004(04)：34.
9.赵丽红.刘嘉湘用温补治疗肿瘤经验[J].黑龙江中医药,1993(5)：4-6.
10.施志明.专家门诊录：温阳补肾治肺癌：随师临诊一得.上海中医药杂志,1990(11)：14-15.
11.郭骏琪.名老中医石玉林治疗乳腺癌骨转移30例.吉林中医药,1998,18(2)：3-4.
12.张丽娟.中西医结合治疗癌性胸腹腔积液36例[J].国医论坛,2001,16(2)：39-40.
13.张勤.中西医结合治疗癌性胸腹腔积液40例[J].河南中医,2013,33(6)：945-946.
14.谢安卫,韩俊.益气温阳汤治疗肿瘤化疗引起白细胞减少临床研究[J].辽宁中医药大学学报,2010,12(1)：140-141.
15.张爱萍,蔡焦生,范红燕等.益气温阳方治疗癌性发热46例[J].中国民间疗法,2011,19(5)：39-40.
16.张侠,刘端祺,刘彦珠.温阳散结中药对裸鼠移植性肝癌生长及微血管密度的影响.中国药学杂志,2000,35(4)：297.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |